Cite
Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.
MLA
Rosa, Kristi. “Pembrolizumab/Axitinib Sustains Efficacy in CcRCC at 5-Year Follow-Up.” Urology Times, vol. 51, no. 8, Aug. 2023, pp. 14–15. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=170257144&authtype=sso&custid=ns315887.
APA
Rosa, K. (2023). Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up. Urology Times, 51(8), 14–15.
Chicago
Rosa, Kristi. 2023. “Pembrolizumab/Axitinib Sustains Efficacy in CcRCC at 5-Year Follow-Up.” Urology Times 51 (8): 14–15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=170257144&authtype=sso&custid=ns315887.